MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ Pharmaceuticals, Biotechnology & Drugs
CorMedix Inc. (NASDAQ: CRMD)*
Organization & Developments: CorMedix
Parents
CorMedix Inc. (NASDAQ: CRMD)*
Children
*CorMedix Inc. (NYSEMKT:CRMD) is a commercial-stage biopharmaceutical company, focused on therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
*Its lead product candidate Defencath, marketed in Europe and other territories as Neutrolin, a CE-marked medical device, is an antimicrobial and antifungal solution designed to prevent catheter-related bloodstream infections ("CRBSIs") in patients with end-stage renal disease ("ESRD") receiving hemodialysis ("HD") through a central venous catheter ("CVC").
2020: CorMedix: Patent Coverage Is A Problem
2021: CorMedix: CRL Resolution Likely
2021: CorMedix: Resolvable CRL And Low Price Make It Attractiv
2023: US FDA approves CorMedix's drug for bloodstream infections
2024: CorMedix 2.0: New Leadership, New Approval, New Focus
2024: CorMedix enters multiyear commercial supply contract
2024: CorMedix Inc. (NASDAQ:CRMD): When Will It Breakeven?
2024: CorMedix: Delayed Approval, Low Cash, Good Prospects
2025: CorMedix: Exceeding Expectations
2025: CorMedix: Finally In Commercialization Mode
Jumps
Finance & Acquisitions: CorMedix
Key People : CorMedix